Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

1993

Henke C, Marineili W, Jessurun J, Fox J, Harms D, Peterson M, et al. Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury. Am J Pathol. 1993;143(4):1189-99.

Chen JM, Barr ML, Chadburn A, Frizzera G, Schenkel FA, Sciacca RR, et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg. 1993;56(3):527-38.

Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation. 1993;55(4):901-8.

Sherman W, Liu Z, Inghirami G, Reed EF, Harris PE, Suciu-Foca NM. Major histocompatibility complex-restricted recognition of autologous chronic lymphocytic leukemia by tumor-specific T cells. Immunol Res. 1993;12(4):338-48.

Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81(10):2708-13.

Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol. 1993;143(3):845-56.

Everett R, Cross A, Tyler J, Orr A. An epitope within the DNA-binding domain of the herpes simplex virus immediate early protein Vmw175 is conserved in the varicella-zoster virus gene 62 protein. J Gen Virol. 1993;74 ( Pt 9):1955-8.

Fabbretti G, Valenti C, Loda M, Brisigotti M, Cozzutto C, Tonini GP, et al. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol. 1993;24(3):294-7.

Garrett TJ, Chadburn A, Barr ML, Drusin RE, Chen JM, Schulman LL, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer. 1993;72(9):2782-5.

Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production. Transplant Proc. 1993;25(1 Pt 1):823-4.